AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. DTIL
  4. [Form 4] Precision BioSciences, Inc. Insider Trading Activity

[Form 4] Precision BioSciences, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Precision BioSciences (NASDAQ: DTIL) filed a Form 4 reporting that director Melinda Brown purchased 1,682 common shares on June 25 2025 at a weighted-average price of $4.14鈥�$4.15. Following the transaction, Brown鈥檚 direct beneficial ownership increased to 20,565 shares.

No other non-derivative or derivative transactions were disclosed, and there were no sales. The filing contains a standard footnote explaining the weighted-average price range. No 10b5-1 trading plan box was checked.

Precision BioSciences (NASDAQ: DTIL) ha presentato un Modulo 4 segnalando che la direttrice Melinda Brown ha acquistato 1.682 azioni ordinarie il 25 giugno 2025 a un prezzo medio ponderato di 4,14鈥�4,15 $. Dopo l'operazione, la propriet脿 diretta di Brown 猫 aumentata a 20.565 azioni.

Non sono state rivelate altre transazioni n茅 derivative n茅 non derivative, n茅 vendite. Il documento contiene una nota standard che spiega l'intervallo del prezzo medio ponderato. Nessuna casella relativa a un piano di trading 10b5-1 猫 stata selezionata.

Precision BioSciences (NASDAQ: DTIL) present贸 un Formulario 4 informando que la directora Melinda Brown 肠辞尘辫谤贸 1,682 acciones ordinarias el 25 de junio de 2025 a un precio promedio ponderado de $4.14鈥�$4.15. Tras la transacci贸n, la propiedad directa de Brown aument贸 a 20,565 acciones.

No se divulgaron otras transacciones ni derivadas ni no derivadas, y no hubo ventas. La presentaci贸n incluye una nota est谩ndar que explica el rango del precio promedio ponderado. No se marc贸 ninguna casilla relacionada con un plan de trading 10b5-1.

Precision BioSciences (NASDAQ: DTIL)電� 鞚挫偓 Melinda Brown臧赌 2025雲� 6鞗� 25鞚�鞐� 臧赌欷� 韽夑窢 臧赌瓴� $4.14鈥�$4.15搿� 1,682欤�鞚� 氤错喌欤茧ゼ 毵れ垬頄堧嫟瓿� 鞁犼碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞚� 瓯半灅 頉� Brown鞚� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 20,565欤�搿� 歃濌岸捻枅鞀惦媹雼�.

雼るジ 牍勴寣靸� 霕愲姅 韺岇儩 瓯半灅電� 瓿店皽霅橃 鞎婌晿鞙茧┌, 毵る弰霃� 鞐嗢棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 臧赌欷� 韽夑窢 臧赌瓴� 氩旍渼毳� 靹る獏頃橂姅 響滌 臧侅＜臧赌 韽暔霅橃柎 鞛堨姷雼堧嫟. 10b5-1 瓯半灅 瓿勴殟 氚曥姢電� 靹犿儩霅橃 鞎婌晿鞀惦媹雼�.

Precision BioSciences (NASDAQ: DTIL) a d茅pos茅 un formulaire 4 indiquant que la directrice Melinda Brown a achet茅 1 682 actions ordinaires le 25 juin 2025 脿 un prix moyen pond茅r茅 de 4,14鈥�4,15 $. Suite 脿 cette transaction, la propri茅t茅 directe de Brown est pass茅e 脿 20 565 actions.

Aucune autre transaction, d茅riv茅e ou non d茅riv茅e, n鈥檃 茅t茅 divulgu茅e, et aucune vente n鈥檃 eu lieu. Le d茅p么t contient une note standard expliquant la fourchette du prix moyen pond茅r茅. Aucune case relative 脿 un plan de n茅gociation 10b5-1 n鈥檃 茅t茅 coch茅e.

Precision BioSciences (NASDAQ: DTIL) reichte ein Formular 4 ein, in dem berichtet wurde, dass die Direktorin Melinda Brown am 25. Juni 2025 1.682 Stammaktien zu einem gewichteten Durchschnittspreis von erworben hat. Nach der Transaktion erh枚hte sich Browns direkte Beteiligung auf 20.565 Aktien.

Es wurden keine weiteren nicht-derivativen oder derivativen Transaktionen offengelegt, und es gab keine Verk盲ufe. Die Einreichung enth盲lt eine Standardfu脽note, die die Preisspanne des gewichteten Durchschnitts erkl盲rt. Kein 10b5-1-Handelsplan wurde angekreuzt.

Positive
  • None.
Negative
  • None.

Precision BioSciences (NASDAQ: DTIL) ha presentato un Modulo 4 segnalando che la direttrice Melinda Brown ha acquistato 1.682 azioni ordinarie il 25 giugno 2025 a un prezzo medio ponderato di 4,14鈥�4,15 $. Dopo l'operazione, la propriet脿 diretta di Brown 猫 aumentata a 20.565 azioni.

Non sono state rivelate altre transazioni n茅 derivative n茅 non derivative, n茅 vendite. Il documento contiene una nota standard che spiega l'intervallo del prezzo medio ponderato. Nessuna casella relativa a un piano di trading 10b5-1 猫 stata selezionata.

Precision BioSciences (NASDAQ: DTIL) present贸 un Formulario 4 informando que la directora Melinda Brown 肠辞尘辫谤贸 1,682 acciones ordinarias el 25 de junio de 2025 a un precio promedio ponderado de $4.14鈥�$4.15. Tras la transacci贸n, la propiedad directa de Brown aument贸 a 20,565 acciones.

No se divulgaron otras transacciones ni derivadas ni no derivadas, y no hubo ventas. La presentaci贸n incluye una nota est谩ndar que explica el rango del precio promedio ponderado. No se marc贸 ninguna casilla relacionada con un plan de trading 10b5-1.

Precision BioSciences (NASDAQ: DTIL)電� 鞚挫偓 Melinda Brown臧赌 2025雲� 6鞗� 25鞚�鞐� 臧赌欷� 韽夑窢 臧赌瓴� $4.14鈥�$4.15搿� 1,682欤�鞚� 氤错喌欤茧ゼ 毵れ垬頄堧嫟瓿� 鞁犼碃頃橂姅 Form 4毳� 鞝滌稖頄堨姷雼堧嫟. 鞚� 瓯半灅 頉� Brown鞚� 歆侅爲 氤挫湢 欤检嫕 靾橂姅 20,565欤�搿� 歃濌岸捻枅鞀惦媹雼�.

雼るジ 牍勴寣靸� 霕愲姅 韺岇儩 瓯半灅電� 瓿店皽霅橃 鞎婌晿鞙茧┌, 毵る弰霃� 鞐嗢棃鞀惦媹雼�. 鞝滌稖 靹滊鞐愲姅 臧赌欷� 韽夑窢 臧赌瓴� 氩旍渼毳� 靹る獏頃橂姅 響滌 臧侅＜臧赌 韽暔霅橃柎 鞛堨姷雼堧嫟. 10b5-1 瓯半灅 瓿勴殟 氚曥姢電� 靹犿儩霅橃 鞎婌晿鞀惦媹雼�.

Precision BioSciences (NASDAQ: DTIL) a d茅pos茅 un formulaire 4 indiquant que la directrice Melinda Brown a achet茅 1 682 actions ordinaires le 25 juin 2025 脿 un prix moyen pond茅r茅 de 4,14鈥�4,15 $. Suite 脿 cette transaction, la propri茅t茅 directe de Brown est pass茅e 脿 20 565 actions.

Aucune autre transaction, d茅riv茅e ou non d茅riv茅e, n鈥檃 茅t茅 divulgu茅e, et aucune vente n鈥檃 eu lieu. Le d茅p么t contient une note standard expliquant la fourchette du prix moyen pond茅r茅. Aucune case relative 脿 un plan de n茅gociation 10b5-1 n鈥檃 茅t茅 coch茅e.

Precision BioSciences (NASDAQ: DTIL) reichte ein Formular 4 ein, in dem berichtet wurde, dass die Direktorin Melinda Brown am 25. Juni 2025 1.682 Stammaktien zu einem gewichteten Durchschnittspreis von erworben hat. Nach der Transaktion erh枚hte sich Browns direkte Beteiligung auf 20.565 Aktien.

Es wurden keine weiteren nicht-derivativen oder derivativen Transaktionen offengelegt, und es gab keine Verk盲ufe. Die Einreichung enth盲lt eine Standardfu脽note, die die Preisspanne des gewichteten Durchschnitts erkl盲rt. Kein 10b5-1-Handelsplan wurde angekreuzt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Brown Melinda
(Last) (First) (Middle)
C/O PRECISION BIOSCIENCES, INC.
302 E. PETTIGREW STREET, SUITE A-100
(Street)
DURHAM NC 27701
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PRECISION BIOSCIENCES INC [ DTIL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/25/2025 P 1,682 A $4.14(1) 20,565 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.14 to $4.15. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
Remarks:
/s/ Dario Scimeca, Attorney-in-fact for Melinda Brown 06/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many DTIL shares did director Melinda Brown buy on June 25, 2025?

The Form 4 shows a purchase of 1,682 common shares.

What is Melinda Brown鈥檚 total direct ownership after the reported transaction?

After the purchase, Brown now directly owns 20,565 DTIL shares.
Stock DTIL logo
Precision Biosciences

NASDAQ:DTIL

DTIL Rankings

#7801 Ranked by Market Cap
N/A Ranked by Dividends

DTIL Latest News

Aug 6, 2025
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
Aug 4, 2025
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
Jul 23, 2025
Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
Jul 16, 2025
Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
Jun 25, 2025
Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

DTIL Latest SEC Filings

Aug 6, 2025
[SCHEDULE 13G/A] Precision BioSciences, Inc. SEC Filing
Aug 6, 2025
[SCHEDULE 13G/A] Precision BioSciences, Inc. SEC Filing
Aug 6, 2025
[8-K] Precision BioSciences, Inc. Reports Material Event
Jul 8, 2025
[Form 4] Precision BioSciences, Inc. Insider Trading Activity
Jul 3, 2025
[144] Precision BioSciences, Inc. SEC Filing

DTIL Stock Data

53.89M
9.71M
10.94%
42.34%
9.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
DURHAM